A Phase 4 interventional study of Climara PRO (Estradiol / Levonorgestrel transdermal) and Menostar (Estradiol transdermal) in Hot Flashes, sponsored by Bayer. Completed at 45 sites in United States. Open to female participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2009-05-29.
Sponsored by Bayer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing estradiol in Hot Flashes — none open to participants now, none under way, none of them phase 3. Estradiol · Hot Flashes.
Among the 13 studies testing estradiol in Hot Flashes, this one is the 8th largest by enrollment, is one of 3 that started in 2004, is the only one in phase 4, and was the 2nd registered.
339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.
Browse Hot Flashes studies →None of the 13 studies testing estradiol in Hot Flashes is open now. The open studies under Hot Flashes, anywhere →
Estradiol: first FDA approval 1954 (DELESTROGEN), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 40 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 9 · Phase 4 1
First in 2003; this study’s year is marked. 3 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 425 is above the median of 90 across 306 interventional studies indexed under Hot Flashes.
Median enrollment 431 across the 13 interventional studies. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 13 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
18 studies in Hot Flashes by Bayer: none open now, 1 under way, 1 of them phase 3. Of 17 finished, 7 (41%) have results posted.
Among the 18 studies in Hot Flashes by Bayer, this one is the 5th largest by enrollment, is the only one that started in 2004, is the only one in phase 4, and was the 2nd registered.
Bayer’s Hot Flashes studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing estradiol in Hot Flashes, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bayer’s 18 in Hot Flashes:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To determine the lowest effective dose of estradiol by comparing E2/LNG (2.2mg/0.69mg) and E2 (1.0mg) dose with placebo in decreasing the frequency and severity of moderate to severe hot flushes in postmenopausal women
This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.
Bayer HealthCare Pharmaceuticals, Inc.is the sponsor of the trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Climara PRO (Estradiol / Levonorgestrel transdermal)
Drug: Menostar (Estradiol transdermal)
Drug: Placebo transdermal
2.2mg 17 Beta-estradiol/0.69mg levonorgestrel combination transdermal patch
Drug pages: Estradiol · Ethinyl Estradiol
1mg 17 Beta-estradiol transdermal patch
Placebo
Lowest effective dose in decreasing the frequency and severity of hot flushes
Other symptoms related to menopause
The record gives a start of Dec 2004 and a completion of Feb 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Estradiol · Ethinyl Estradiol